0001415889-24-009885.txt : 20240402 0001415889-24-009885.hdr.sgml : 20240402 20240402204206 ACCESSION NUMBER: 0001415889-24-009885 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240402 FILED AS OF DATE: 20240402 DATE AS OF CHANGE: 20240402 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Wellington Biomedical Innovation Master Investors (Cayman) I L.P. CENTRAL INDEX KEY: 0001787092 ORGANIZATION NAME: STATE OF INCORPORATION: E9 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41989 FILM NUMBER: 24816612 BUSINESS ADDRESS: STREET 1: WELLINGTON ALTERNATIVE INVESTMENTS LLC STREET 2: 280 CONGRESS STREET CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: (617) 951-5372 MAIL ADDRESS: STREET 1: WELLINGTON ALTERNATIVE INVESTMENTS LLC STREET 2: 280 CONGRESS STREET CITY: BOSTON STATE: MA ZIP: 02210 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Boundless Bio, Inc. CENTRAL INDEX KEY: 0001782303 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 830751369 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 9880 CAMPUS POINT DRIVE STREET 2: SUITE 120 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: (858) 766-9912 MAIL ADDRESS: STREET 1: 9880 CAMPUS POINT DRIVE STREET 2: SUITE 120 CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 form4-04032024_120459.xml X0508 4 2024-04-02 0001782303 Boundless Bio, Inc. BOLD 0001787092 Wellington Biomedical Innovation Master Investors (Cayman) I L.P. C/O WELLINGTON MANAGEMENT COMPANY LLP 280 CONGRESS STREET BOSTON MA 02210 false false true false 0 Common Stock 2024-04-02 4 C 0 189933 A 189933 D Common Stock 2024-04-02 4 C 0 366300 A 556233 D Series B Preferred Stock 2024-04-02 4 C 0 3703704 0 D Common Stock 189933 0 D Series C Preferred Stock 2024-04-02 4 C 0 7142857 0 D Common Stock 366300 0 D On April 2, 2024, the Series B Preferred Stock automatically converted into Common Stock on a 19.5-for-1 basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The Series B Preferred Stock had no expiration date. On April 2, 2024, the Series C Preferred Stock automatically converted into Common Stock on a 19.5-for-1 basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The Series C Preferred Stock had no expiration date. Wellington Biomedical Innovation Master Investors (Cayman) II L.P. By: Wellington Management Company LLP, as Investment Adviser /s/ Peter McIsaac, Title: Authorized Person 2024-04-02